Clinical Research

EndoSure is licenced by the MHRA and has a CE mark for clinical use in the UK and Europe. In spite of this the EndoSure device continues to be evaluated extensively in the US, UK and Europe with a number of ongoing studies.

  • Blinded controlled trial to study the accuracy of EndoSure in women undergoing surgery for known endometriosis, and for benign conditions, other than confirmed endometriosis.
  • Evaluation of EndoSure in populations of teenagers with dysmenorrhea
  • Evaluation of EndoSure and subjects with prior history of endometriosis and recurring symptoms post surgery.
  • Evaluation of EndoSure as an index measurement of response to surgery or medical therapy in subjects with known endometriosis
  • Open label initial evaluation of EndoSure.
  • Comparative trial to study the accuracy of EndoSure and #Enzian classification in women with endometriosis.
  • Controlled trial to study the accuracy of EndoSure in women undergoing surgery for known endometriosis, and for benign conditions, other than confirmed endometriosis.
  • Trial to study the accuracy of EndoSure in women undergoing surgery for known endometriosis, and for benign conditions, other than endometriosis.

Publications

Relation of endometriosis and neuromuscular disease of the gastrointestinal tract: new insights. J R Mathias, R Franklin, D C Quast, N Fraga, C A Loftin, L Yates, V Harrison. Fertil Steril 1998 Jul;70(1):81-8.

AI-Derived Threshold Score of Intraabdominal Myoelectrical Activity Predicts Presence and Stage of Endometriosis with 100% Accuracy. Noar M. Journal of Minimally Invasive Gynecology 2022. Nov/Dec;29(11) Supplement

Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis
Noar, M.; Mathias, J.; Kolatkar, A. Gastrointestinal Myoelectrical Activity (GIMA) Biomarker for Noninvasive Diagnosis of Endometriosis. J. Clin. Med. 2024, 13,2866.